To determine whether this characteristic heightens bleeding risk in patients with renal insufficiency, researchers in Connecticut compared bleeding rates with enoxaparin and UFH in a retrospective ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study. By creating the most complete and detailed genetic 'map' of kidney function to ...

"Heart failure and kidney failure often go hand in hand," he told Newsweek, adding that the kidneys control the way the body handles salt and water. If they are not getting rid of these substances ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Now aged 32, the entrepreneur is sharing his story to raise awareness of kidney disease, which affects 35.5 million Americans, according to the American Kidney Fund. Blake Shusterman, a ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...